NextGem has basic technologies to identify and isolate hematopoietic stem cells which are active over a long time, a very small portion of hematopoietic stem cells with the proportion of around 1 cell in 100,000 cells of mouse bone marrow cells. The company applies AI and bioinformatics technology including machine learning to reveal such cells more efficiently and to develop new therapeutic methods based on such stem cells.